US007335799B2

(12) **United States Patent**
Dasseux et al.

(10) **Patent No.: US 7,335,799 B2**
(45) **Date of Patent: Feb. 26, 2008**

(54) **HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES**

(75) Inventors: **Jean-Louis Henri Dasseux**, Brighton, MI (US); **Carmen Daniela Oniciu**, Ann Arbor, MI (US)

(73) Assignee: **Esperion Therapeutics, Inc.**, Ann Arbor, MI (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 711 days.

(21) Appl. No.: **10/743,470**

(22) Filed: **Dec. 23, 2003**

(65) **Prior Publication Data**

US 2005/0043278 A1 Feb. 24, 2005

Related U.S. Application Data

(60) Provisional application No. 60/441,795, filed on Jan. 23, 2003.

(51) **Int. Cl.**
C07C 31/22 (2006.01)
C07C 31/20 (2006.01)
C07C 31/18 (2006.01)

(52) **U.S. Cl.** **568/861**; 568/852; 568/858; 568/859; 568/860; 568/864; 562/512; 562/517; 562/519; 560/190; 560/203; 560/204

(58) **Field of Classification Search** 568/852, 568/858, 859, 860, 861, 864; 562/512, 517, 562/519; 560/190, 203, 204
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,152,148	A	10/1964	Easterly et al.
3,441,605	A	4/1969	Blake et al.
3,773,946	A	11/1973	Creger
3,930,024	A	12/1975	Creger
4,287,200	A	9/1981	Kawamatsu et al.
4,584,321	A	4/1986	Manghisi et al.
4,613,593	A	9/1986	Yamatsu et al.
4,634,719	A	1/1987	Takaishi et al.
4,689,344	A	8/1987	Bar-Tana
4,711,896	A	12/1987	Bar-Tana et al.
4,714,762	A	12/1987	Hoefle et al.
5,166,174	A	11/1992	Ueno et al.
5,225,439	A	7/1993	Ueno et al.
5,284,858	A	2/1994	Ueno et al.
5,380,709	A	1/1995	Ueno et al.
5,428,062	A	6/1995	Ueno et al.
5,502,198	A	3/1996	Picard et al.
5,504,073	A	4/1996	Homan
5,578,639	A	11/1996	Homan
5,633,287	A	5/1997	Lee et al.
5,648,387	A	7/1997	Bisgaier et al.
5,750,569	A	5/1998	Bisgaier et al.
5,756,344	A	5/1998	Onda et al.
5,756,544	A	5/1998	Greger et al.
5,783,600	A	7/1998	Bisgaier et al.
5,834,596	A	11/1998	Ageland et al.
5,886,034	A	3/1999	Ueno et al.
5,968,963	A	10/1999	Homan
5,981,595	A	11/1999	Picard et al.
6,004,925	A	12/1999	Dasseux et al.
6,017,905	A	1/2000	Roark et al.
6,037,323	A	3/2000	Dasseux
6,093,719	A	7/2000	Bocan
6,093,744	A	7/2000	Lee et al.
6,124,309	A	9/2000	Bocan
6,143,755	A	11/2000	Bocan
6,459,003	B1	10/2002	Dasseux et al.
6,646,170	B2	11/2003	Dasseux et al.
6,673,780	B2	1/2004	Dasseux et al.
6,699,910	B2	3/2004	Dasseux et al.
6,703,422	B2	3/2004	Dasseux et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0 284 108	9/1987

(Continued)

OTHER PUBLICATIONS

Bicking, et al., "11,12-Secoprostaglandins. I. Acylhydroxyalkanoic acids and related compounds", J. Med. Chem., 1977, pp. 35-43, vol. 20.

Nagano H, et al., "Stereoselectivity in the formation and radical reduction of cyclic bromoacetals, key intermediates for the sythesis of delta-hydroxy-and epsilon-hydroxy-alpha-methylcarboxylic acid esters", Tetrahedron Letters, 2003, pp. 6867-6870, vol. 44, No. 36.

Bobrova, et al., abstract, J. Org. Chem, 1983, pp. 259-261, vol. 19.

Narasaka, et al., abstract, Bull. Chem. Soc, 1987, pp. 1457-1464, vol. 60, No. 4.

(Continued)

Primary Examiner—Elvis O. Price
(74) *Attorney, Agent, or Firm*—William R. Boudreaux; Martha A. Gammill; Charles W. Ashbrook

(57) **ABSTRACT**

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

18 Claims, No Drawings